Dataset Information

Electricity prices in Italy: Data registered during photovoltaic activity interval.

ABSTRACT: Data we present in this article are related to the research article by Bertolini M., D'Alpaos C. and Moretto M. "Do Smart Grids boost investments in domestic PV plants? Evidence from the Italian electricity market"(Bertolini et al., 2018) [1]. The dataset is an elaboration of historical spot prices provided by the Italian Gestore dei Mercati Energetici (GME) and gives information about average prices registered during the day, when photovoltaic (PV) plants are - on average - expected to produce energy. Prices are stated in €/MWh.

SUBMITTER: Bertolini M

PROVIDER: S-EPMC6141157 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Electricity prices in Italy: Data registered during photovoltaic activity interval.

Bertolini Marina M D'Alpaos Chiara C Moretto Michele M

Data in brief 20180619

Data we present in this article are related to the research article by Bertolini M., D'Alpaos C. and Moretto M. "Do Smart Grids boost investments in domestic PV plants? Evidence from the Italian electricity market"(Bertolini et al., 2018) [1]. The dataset is an elaboration of historical spot prices provided by the Italian Gestore dei Mercati Energetici (GME) and gives information about average prices registered during the day, when photovoltaic (PV) plants are - on average - expected to produce ...[more]

PMID: 30229015

Similar Datasets

Project description:ObjectiveTo investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation.DesignRetrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes.SettingWe did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy.Main outcomes and measuresInformation on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients β, their levels of significance p and the coefficients of determination R2 were estimated adjusting by tumour type.ResultsOverall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price (R2=0.067, n=16 drugs for 17 indications). When the clinical outcomes were expressed as improvements in the median PFS or ORR, 25 drugs (29 indications) were available for the analysis, and again, there was no correlation with prices (R2=0.004 and 0.006, respectively).Conclusions and relevanceOur results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.

Dataset Information

Electricity prices in Italy: Data registered during photovoltaic activity interval.

Publications

Electricity prices in Italy: Data registered during photovoltaic activity interval.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure